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ABSTRACT 
Visual acuities were measured through a series of prisms in order to quantify the blur 
that results from dispersion in polycarbonate. The mean VA of forty eyes declined from 
20/13 unaided to 20/31 through 16 prism diopters of polycarbonate. The decline was a 
linear function of prismatic power. The blurring effect of polycarbonate was 
significantly greater than that of CR39. The blur from polycarbonate was found to be 
great enough that it should be taken into account whenever polycarbonate is considered 
for spectacle lenses. Graphical displays are provided which can be used by the clinician 
to predict the degree of blur from a known polycarbonate lens. 
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FIGURES AND TABLES 
TABLE 1 Mean Minimum Angles of Resolution (M.A.R.) Follows page 7 
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INTRODUCTION 
The extremely high impact resistance of polycarbonate is well known .1 It has 
been widely used for several years in helmets, shields, nonprescription protective 
glasses, and other safety applications. Possessing additional advantages of light weight, 
ultraviolet absorption, and high index of refraction, it is increasingly being used for 
prescription ophthalmic lenses. 
Recent litigation results make it clear that the prescriber, dispenser, and 
manufacturer of ophthalmic goods are all legally obligated to recommend the safest 
spectacle materials to the patient. The impact resistance advantages of polycarbonate 
have led to its recommendation as the lens material of choice in circumstances of 
significant risk, such as in industry and with sports, children, and monocular patients. 
This is urged by legal authorities in optometry and by the optical industry as wel\.2-7 
The polycarbonate share of the U.S. ophthalmic lens market, presently approximately 
six percent, a is likely to increase because of this liability. 
A drawback, however, is the relatively high dispersion of polycarbonate. This 
characteristic, also known as constringence, can lead to color fringes and loss of 
image clarity in the periphery of prescription lenses. As it is a function of prismatic 
power, the effect increases with stronger lenses and increased eccentricity of gaze. 
Patients have been known to reject polycarbonate lenses for this reason.8,9 
But how much blur does it cause? Although it is generally known that 
polycarbonate causes significant dispersion, practitioners lack quantitative information 
on the resultant blur. It would be useful to prescribers to know how much the visual 
acuity could be expected to decline for a known lens power and eccentricity of gaze. 
Patient counseling could then be made more specific, less vague. Dr. Smith could tell 
Mrs. Jones, "With your prescription, if you look this far from the center of your 
lenses, your vision clarity will be reduced to this level." The doctor could use a Snellen 
chart to demonstrate the predicted loss of acuity, and could determine whether the blur 
was acceptable to the patient and compatible with the patient's visual needs . 
The purpose of this paper is to provide that quantitative information. This study 
measured the degradation of visual acuity (VA) as it relates to prismatic power . The 
question asked was this: "How much does VA decline for a given prism power, and is 
that decline statistically and clinically significant?" The effect of ophthalmic lens 
materials of high dispersive power, polycarbonate. and low dispersive power, CR39, 
were studied and compared against each other. 
The measure of a material's dispersion is the coefficient of mean 
dispersion (the nu value, or v. also referred to as the Abbe number). It is 
calculated by the follow ing formula: 10 
ne - 1 
v = -----
nF' - nc 
In this formula, ne is the refractive index for mercury green (5<46.1 nm), nF· is the 
refrac ti ve index for cadmium blue (L\80.0 nm). and nc is the refractive index for 
cadmium red (6<43.8 nm). The refractive index for short wavelengths (blue) is greater 
than that for long wavelengths (red). 
With a relatively small difference between the indices of refraction at the two 
extremes of the visible spectrum, i .e. with low dispersion, the denominator in the 
formula will be small and v will be a relatively large number . Conversely. with a 
larger difference between the indices at the red and blue ends of the spectrum. i.e. with 
high dispersion, the denom inator will be larger and v will be a relatively small number. 
In other words, vis an inverse func.tion of dispersion; the greater the tendency of a 
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material to disperse white light into its spectra l components, the lower will be its 
coefficient of mean dispersion (v). 
Polycarbonate has a v value of 30.8 '9 ' 11 The v of crown glass and CR39 are 
essentially equal; vCCR39) is 58 and v(crown glass) is 58 .8. 10 
The chromatic power (CP) is a means of describing the dispersion of a 
. r· . 12 spec1 1c pnsm. 
CP =prismatic effect. 
v 
The chromatic power of a material increases as v decreases and as the prismatic effect 
increases . Thus, since v of polycarbonate is half that of crown glass and CR39, its 
chromatic power is twice that of crown glass and CR39 for a given amount of pr ism. 
The dispersive power of polycarbonate was considered in the design of the Gentex 
polycarbonate lens series .13, 14 No claim was made that the high dispersion could be 
overcome, rather that the resultant blur made it impera tive that the lens design must 
minimize other errors. Concern for this problem led to the manufacturer's 
recommendation for extra care in surfacing (base curve selection is critical) and in the 
fitting of polycarbonate lenses. 15 
The effect of dispersion on visual acuity has been studied by ·Mesl in and 
Obrecht.12 Using plano pr isms of various materials, they established a ser ies of 
increasing chromatic powers through which they measured visual acuities. Though they 
foun d that dispersion had a significant effect on visual acuity, t heir conclusions were 
that it should not preclude the use of high constringence materials for spectacle lenses. 
Since visual acuity is not an interval scale, the standard statistical manipulations of the 
decimal acuity data in that study are questionable. 15 In no way does that invalidate the 
study, however. and the present experiment pursues a similar method. 
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METHODOLOGY 
We chose to use prisms rather than prescriptlon ophthalmic lenses for several 
reasons. Most importantly, it is a means by which the oblique aberrations of coma, 
oblique astigmatism, and distortion can be excluded, along with lens design 
characteristics. Those wi l l vary in degree depending on the angle of gaze through the 
lens and the design of the lens, and are not characteristics which are being studied here . 
With the use of prisms, chromatic dispersion is isolated as the opt ical characteristic 
which distinguishes the two materials . 
A major regional supplier of polycarbonate spectacle lenses fabricated two sets of 
plano prisms for this study, one set of polycarbonate and one set of CR39. Each set 
consisted of eight prisms of these powers : 2, t::l, 6, 8, 1 0, 1 2, 1 t::l, and 1 6 prism diopter s . 
This produced a graduated series of prisms of high constringence (polycarbonate, V"'30) 
and a matching series of prisms of low constringence (CR39, V"'58), sixteen prisms all 
together . (The true powers varied from the stated power by 1/2 prism diopter in five 
prisms. The 1 t::l and 16 diopter polycarbonate prisms were measured at 13.5 and 15.5 
prism diopters respective ly. The 6, 1 t::l, and 16 diopter CR39 prisms were actually 
6 .5, 1 4 .5, and 16 .5 diopters respectively.) 
The experimental population consisted of 40 essential l y emmetropic eyes, the 
selection criterion be ing 20/20 (6/6) or better uncorrected visual acuity. Two 
subjects had only one qualifying eye; there were 21 subjects altogether, 1 t::l males and 7 
females. Subjects wer e students, faculty members, and family members of students and 
faculty at Pacific Unive r si ty, Forest Grove, OR . All subjects were volunteers. Their 
ages ranged from 24 to 63 years. 
Visual acuity was measured for each subject eye in the unaided state and through 
each of the sixteen prisms, seventeen measures in all. The prisms were placed before 
the tested eye in the back cell of a tr ial frame. The contralateral eye was occluded by an 
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opaque disk, also in the rear-most cell. The laboratory edged the prisms so that the trial 
lens ring was at the posterior (ocular) surface; all ocular surfaces were therefore 
normal to the visual axis when the prisms were placed into the trial frame. No 
additional corrective trial lenses were used, hence there were no multiple lens surfaces 
to present a confounding variable in VA testing. 
We modified a first-generation Baylor Visual Acuity Tester CBVA T) to produce 
optotype size increments of 2 1/2 feet (Snellen), equal to one eighth of a minute of arc. 
This permitted very small changes of optotype size and consequently fine measurements 
of VA. For example, between the visual acuities 20/10 and 20/20 were the following 
values: 20/10 (.5 min.), 20/12.5 (.625 min.), 20/15 (.75 min.), 20/17.5 (.875 
min.) and 20/20 ( 1.0 min.). 
The experimenter tested the subject's right eye first, starting with unaided VA. 
The prisms were then placed in the trial frame in random sequence, and the VA was 
measured through each. The left eye was then tested in the same manner. 
Letters were used as the testing optotypes. The psychophysical technique used in 
data gathering was an adaptation of the method of limits. Three runs, starting 
alternately above and below threshold, were conducted under each of the seventeen 
conditions (unaided and each prism value). Each run consisted of a sequence of 
increasingly larger (if below threshold) or increasingly smaller (if above threshold) 
presentations of five teslletlers. The letters were randomly changed upon each 
presentation. The end point value was the smallest optotype size which was identified 
80r. (four of five) correctly. The three end point values were converted from visual 
acuity notation into minutes of arc and averaged to produce that subject eye's minimum 
angle of resolution (MAR) for each of the seventeen testing conditions. MAR means were 
then calculated for the entire experimental group. 
The BVAT monitor screen was produced by Motorola, model number 
M3560-155, incorporating the P4 phosphor. The monitor was masked by an off-white 
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shield with an aperture within which the letters were centered. The testing distance was 
six meters. Ambient room illumination was 172 lux ( 16 foot-candles) as measured by 
the Spectra Candela TM meter (Photo Research). Optotype/screen contrast was 98?., as 
measured by a J 16 digital photometer and a J6523- 2 narrow-angle luminance probe 
(both by Tektron ix) . The monitor screen background lumi nance mean was 292 c/m2 
(nits), as measured by the same Tektronix instruments. Screen lur:ninances were 
measured at the top, right, bottom, and left edges of the exposed portion of the screen, 
and all findings were within 14?. of the mean. 
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RESULTS 
The MAR increased with increas ing prismatic power for both polycarbonate and 
CR39. The degree of the effect, equivalen t to a decline In VA, was much greater with 
polycarbonate. Mean MAR's are presented in Table 1. They are graphically depicted in 
Figure 1. 
The mean unaided MAR was 0.66 minutes of arc, equal to a visual acuity of 
20/13.2. Through bo th materials the mean MAR increase (VA dec line) was fairly 
l inear, reach ing 1 .56 minutes of arc, or 20/31 .2, through 16 prism diopters of 
polycarbonate. This was a MAR increase of 0.90 minutes over the unaide d MAR. 
Through 16 prism diopters of CR39 the mean MAR was 1 .0.:::1 minutes, or 20/20.8, an 
increase of 0.38 minutes over the unaided mean. 
Unaided MAR's ranged from 0 . .:::12 minutes (20/8 . .:::1) to 0.92 minutes 
(20/18.-4) . Similarly, subjects varied in t he degree to which their vision was affected 
by the prisms . Through po lycarbonate , the gre atest MAR differential between unaided 
and 16 prism diopters was 1.79 minutes; the least was 0.50 minutes. Through CR39, 
the greatest MAR increase was 0.91 minutes and the least was 0.08 minutes. 
Three separate one-facto r analyses of variance (ANOVA) for repeated 
measures were performed. The first judged the significance of the effect of 
polycarbonate on MAR. The ANOVA made comparisons between the mean unaided MAR and 
the mean MAR at each prism value increment of the polycarbonate series. With the 
exception of unaided v. 2 prism diopters, all comparisons showed strong statistical 
significance as assessed by the Scheffe F-test. By design, this tes t describes significance 
at the 90?o level. 
The second ANOVA assessed the significance of the effect of CR39 on MAR. It made 
comparisons between the mean unaided MAR and the mean MAR at each step of the CR39 
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FIGURE 1. MINIMUM ANGLE OF RESOLUTION (M.A.R.) es e FUNCTION 
of POL YCARBONATE end CR39 PRISM POWER 
series. In that case, there was no statistical significance at the unaided v. 2, 4 and 6 
prism diopter levels. Unaided v. 8, 10, 12. 14, and 16 prism diopters were significant. 
The third AN OVA compared the polycarbonate and CR39 slopes. It answered this 
question: was the effect of polycarbonate on mean MAR significantly different than the 
effect of CR39 on mean MAR? In order to do this the algebraic difference between mean 
MAR values for polycarbonate and CR39 at each increment on the prism diopter scale 
was calculated. The ANOVA then compared each such difference against that same finding 
at all other points on the scale. (For example, at 4 prism diopters the MAR means were 
0.81 min. for polycarbonate and 0.68 min . for CR39, a difference of 0.13 min. This 
was compared to differences of .06 min. at 2 prism diopters, .22 min. at 6 prism 
diopters, and other values at the other prism diopter increments.) This analysis 
determined that there was no significant difference between MARpoly- MARcR39 
differences at any two adjacent points on the prism diopter scale. When mean MAR 
differences at non-adjacent points were compared, however, they differed with strong 
statistical significance . 
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DISCUSSION 
These results show that image quality is reduced by prisms made of 
polycarbonate and of CR39, and that polycarbonate causes the greater degree of blur. 
Prismatic distortion 17 being equal between the two materials at any given prism power, 
differences can be attributed to chromatic aberration. The blurring effect of 
polycarbonate, as measured by changes in the minimum angle of resolution, is 
statistically significant in all prisms of 4 diopters and greater. The blurring effect of 
CR39, on the other hand, is statistically significant only in prisms of 8 prism diopters 
and stronger . There is strong statistical significance to the difference between the 
polycarbonate and CR39 effects. 
The small power errors in the experimental prisms may slightly reduce the 
apparent difference between the two materials. The 14 and 16 diopter polycarbonate 
prisms were both 1/2 diopter weaker than stated. If the fi ndings are affected at all by 
this sma l l error, it can be presumed that the dispersion and resu l tant blur found at 
those points on the polycarbonate scale are slightly less than if the prisms had been of 
fu ll stated strength. Likewise the 6, 14, and 16 diopter CR39 prisms were each 1/2 
prism diopter stronger than stated . This would cause the blur measured at those points 
on the CR39 sca le to be sl ightly greater than if the prisms were at their stated power. 
The di fferences between the blur effects of polycarbonate and CR39, therefore, may be 
understated to a small degree by this analysis. 
The issue of clinical significance, of course, has greatest meaning to the 
practitioner. The dominant prescription lens materials, CR39 and crown glass, share 
the same low coefficient of dispersion, and their peripheral effects are familiar to 
practitioners and patients. Whatever small degree of clarity is lost due to dispersion or 
other aberrations in the lens periphery is accepted as the norm. Any increase from that 
may be noticed and may become distracting to the patient. If that occurs. or if vision 
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clarity is disturbed enough to interfere with function, then the blurring effect of 
polycarbonate's higher constringence becomes cli ni cally very relevant. 
Figures 2 and 3 can be used in the clinical application of the data. Polycarbonate 
MAR's are converted into Snellen fraction notation. Prismatic effect is converted into 
dioptric power and distance from the center of a prescription lens by use of Prenllce's 
Law 18. The slopes are filled by eye. The slopes depict the visual acuities wh ich will be 
achieved through po lycar bonate lenses of 2.00, •:J.OO, 6 .00, and 8 .00 diopters out to 20 
mm from the center . 
Figure 2 is based on best visual acuity of 20/13, the same as the baseline mean 
VA in this study. Using the example of a 4.00 D polycarbonate lens, if the line of sight 
passes through the lens 20 mm from the center, the resultant VA will be approximately 
20/2 1. If an 8 .00 D lens is used (about the maximum meridional power available in 
finished lens blanks from polycarbonate lens manufacturers), also at 20 mm from the 
center, the VA wi l l be approximately 20/31. 
This study ' s base li ne mean VA of 20/13, however, was measured under ideal 
laboratory cond iti ons with high-resolution optotypes. Accordingly, i t is somewhat 
better than the average bes t VA that can be expected in the cli nic . If the assumption is 
made that the blur effec t i s fairly consistent w i thin a lim i ted range of baseline VA's, 
then the predicted acuity decrement can be applied to any VA w i thin that range. Figure 3 
displays the same slopes as Figure 2 but is based on a starting acuity of 20/20. Using 
this starting point, a 4 .00 D polycarbonate lens at 20 mm from the center yields VA of 
20/28 and an 8.00 lens at 20 mm from the center y iel ds 20/38 . 
Figure 4 presents the acuity decrement for both materials in the form of changes 
in the Snellen denominator. Again, the blur effect is considered a constant within that 
reasonably narrow "normal acuity" range. The ordinate scale is derived from the 
following linear relationship between the denominator of the Snellen visual acuity 
fraction and the Minimum Angle of Resolution: Sne ll en denominator= MAR X 20. (This 
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assumes the 20 foot Snellen standard; e.g. MAR 1.0 minutes of arc is 20/20, MAR 2.0 
minutes is 20/LJO.) Hence, an MAR increase resulting from dispersion blur converts 
direct ly into an increase in U1e Snellen fraction denominator. The original data is plotted 
in that form in Figure L1 and a best-flt l in e is added. Using this slope and us ing 
Prentice's Law to ca lculate prismatic effect, the VA decrement at virtually any point on a 
prescription polycarbonate lens can be predicted. Adding that decrement to the best VA 
yields the estimated VA throu gh that part of t he lens. 
For example, at 20 mm. from the center of a Ll.OO diopter lens there are 8 
diopters of prismatic effect. Figure L1 indicates that 8 diopters of prismatic effect in a 
polycarbonate lens will increase the Snellen denominator by approximately 8 feet, 
decreasing 20/20 visua l acuity to 20/28 . The same amount of pr i sm in CR39 will 
cause 20/20 to decrease on ly to 20/23 . 
The v isual acuity changes ind icated by these best-fit pred iction li nes are 
estimates . And, as the experimental findings clearly show, the blur response varies 
between ind ividuals. Likewise, illumination varies in the real wor ld. The backg round 
illumination provided by t he BVA T' s PLl phosphor was somewha t gray ish, in the manner 
of an overcast sky. The spectra l energy characteristics of other types of illumination 
(e.g. fluorescent lighting, or daylight at noon under a blue sky) are different. and color 
fringes from dispersion will be affected to some degree by those differences. 
The pred icted VA's are best described as optimistic, or "best-case" estimates. 
They repres ent the level to which visual acuity is reduced by the effect of dispersion 
(and, to some degree, prismatic distortion). As discussed previously, the use of prisms 
in this study permitted us to avoid the aberrations present in the periphery of 
prescription lenses, iso lating dispersion as the investigated variable. In clinical 
practice, those aggravating factors will be present in varying degree depending on the 
prescr iption and the lens design. In whatever degree they exist, they will add to the 
degradation of image qual i ty. Visual acu iti es through the periphery of prescription 
1 1 
polycarbonate lenses, therefore, can be expected to be no better, and probably somewhat 
less, than Lhose prediclcd oy Figures 2 - 4. 
These questions arise: "Even if there is greater blur in the periphery of 
polycarbonate lenses, just how important is that? Is it not true that the average person 
turns the head rather than turning just the eyes, so that fixation is as much as possible 
in the straight-ahead position?" Authors disagree on the issue. Adler 19 stales that the 
eyes rotate 30" laterally, 60" to 75" down, and 20· to 30· up "before the head is 
moved." At a vertex distance of 15 mm with 1 o· pan to scopic tilt, those angles of gaze 
equal 9 mm laterally, 20 to 34 mm down, and 6 to 10 mm up. In a study of head and eye 
movement responses to peripheral signals, Bartz20 found that few head movements were 
made in response to stimu li less peripheral than 40· . That angle is equal to 13 mm of 
eccentr icity. In apparent disagreement, Gresty21 determined that when subjects were 
instructed to fixate continuously presented targets alan angle of 14.7", they always 
moved their heads, though there was head movement less than half the time when they 
fixated targets at that same angle that were presented only briefly. At the lens, 14 .7" 
translates to 4 mm from the straight forward pos ition of gaze. Afanador and 
Aitsebaomo22 investigated the range of eye movements at near, using as their criterion 
less than a two degree compensatory head movement. Their study showed a total range, to 
the left and right, of less than 14" (less than 4 mm). Bartz20 further determined that 
head movement in response to a flashed peripheral target was not initiated by foveal 
fixation of that target, and that fixation was not achieved until head movement was 
complete, at which time the angle of turn of the eyes was very small. In other words, no 
foveal fixation occurred until the head was pointed toward the object of regard. 
With the exception of Adler's measure of the depression of gaze for reading, all 
agree that the average person does not commonly fixate at extreme angles which require 
looking through the far lens periphery. It is reasonable to expect that some persons will 
rotate the eyes more, some less, and that the nature of the visual task is a factor (for 
12 
example a brief glance. as wi th using the rear view mirror while driving. versus 
careful fixation with the need for resolving fine detail). With low-power lenses and 
unremarkable visual needs there may be no delectGible blu r or even any persistent color 
fringes . 
But even though steady fixation through the lens edge is not regularly expected, 
personal and clinical experience tell us that clear vision in the periphery of spectacle 
lenses is desirable. Loss of peripheral clarity may be distracting and annoying, 
especially in vocational or recrea tional circumstances which preclude fixation through 
the center of the lens. To the golfer addressing a putt, clear vision through the lens 
periphery is desirable since the head is not easily ro tated to fixate the cup while the 
body is In that position. In some cases peripheral blur could be a handicap. It is not 
difficult to imagine vision-critical industrial situations in which maximum clarity out 
to the edges of the lens is essential for reasons of safety as well as job performance. In 
the military scenario, consider the infantryman aiming at a target with his cheekbone 
pressed against the stock of his rifle, or the je t fighter pilot craning his neck to search 
the sky for aircraft approaching from behind. 
' Clearly, these are not visual requirements encountered with every patient. The 
degree of VA loss found here, however, suggests that the prescriber would be prudent to 
consider whether the off-center blur of polycarbonate possibly creates a functional or 
safety disadvantage that equals or exceeds its impact resistance advantages. 
The conclus ions from this study are that in certain combinations of prescription 
power and eccentricity of gaze there will be significant blurring of vision due to the 
dispersion inherent in po lycarbonate. The loss of image sharpness is great enough that it 
should be considered in the selection of lens mate rials . The reader can use Figures 2 - 4 
to predict the degree of visual acuity which will be lost due to dispersion when looking 
through the periphery of a known polycarbonate lens. 
13 
FOOTNOTES 
a Personal communication with Mr. Gene Keeney, Optical Manufacturers Association 
COMA), 26 JG~nuary 1990. The 1989 ophthalmic lens market shares were the 
following : CR39 73?., glass 21%, and polycarbonate 6%. The OMA predicts that the 
polycarbonate share will begin to increase dramatically due to product liability concerns 
on the part of major optical chains and optical "superstores". 
14 
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APPENDIX A 
Measurement of Luminance and Contrast 
17 
0 
0 0 
0 
Diagram of the Aperture Through Which the S ubiect Vievved tt~e Screen of the Baylor 
Visual Acuity Tester. (The four circles represent the four locations at which the screen 
luminance was measured. A 20/25 optotype was centered on the screen when the 
measurements vvere made.) 
Diagram of the Aperture Through Which the Subject Vievved the Baylor Visual Acuity 
Tester Screen. (The circles represent the locations on the screen which vvere measured 
when the contrast was calculated. A 201200 optotype was centered on the screen when 
the measurements vvere taken.) 
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APPENDIX B 
Example Optotypes 
1 8 
Di agrem of the Aperture Through Which the Subject Viewed the Screen of the 
Baylor Visual Acuity Tester. (Five example optotypes ere shown in the seme 
wey es they would be seen by the subject. At each presentation the optotypes 
were randomly changed by the BVAT microprocessor.) 
APPENDIXC 
Spectral Energy Characteristics of the P4 Phosphor 
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APPENDIX D 
lncrsase jn Snellen Denomjna!Qr and M A,.B . wjlb E_Qiycarbooate and CR3.9 Prism. 
This table provides the data points upon which Figure 4 is based. It was derived from 
the mean M.A.R.'s which are found in APPENDIX E. 
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Condition M.A.R. 
Unaided 0.66 
2 0 .74 
4 0 .81 
6 0.92 
Polycarbonate 8 1.05 
Prism 10 1 .17 
12 1 .31 
14 1.49 
16 1.56 
2 0.68 
4 0 .68 
6 0.70 
CR39 Prism 8 0 .75 
(p.d.) 10 0 .82 
12 0.87 
14 0.95 
16 1.04 
M.A.R. Increase Snellen VA Snellen Denominator 
(from unaided) (201 .... ) Increase (From Unaided) 
- - -
0.08 14.80 1.60 
0.15 16.20 3.00 
0.26 18.40 5.20 
0.39 21.00 7.80 
0 .51 23.40 10.20 
0.65 26.20 13.00 
0.83 29.80 16.60 
0.90 31.20 18.00 
0.02 13.60 0.40 
0.02 13.60 0.40 
0.04 14.00 0.80 
0.09 15.00 1.80 
0.16 16.40 3.20 
0.21 17.40 4.20 
0.29 19.00 5.80 
0.38 20.80 7.60 
--
Increase in Snellen Denominator and M.A.R. 
with Polycarbonate and CR39 Prism. 
I 
I 
i 
--
APPENDIX E 
MAR. Scores 
The scores in this table (Microsoft EXCEL} represent the mean M.A.R.'s for each subject 
for each testing condition. The 40 subjects are listed in column 1 . Column 2 is the 
subject's unaided M.A.R. The remaining 16 columns are the subject's M.A.R.'s for each 
prism value on the polycarbonate scale and on the CR39 scale. As discussed in the 
Methods section, each M.A.R. entry is itself the mean of three visual acuity 
measurements which have been converted into minutes of arc. 
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M.A.A. Scores (EHCH) 
UNRIDED POLVCARBONATE CA 39 
,~U8JECT I P2 P4 Pt6 P9 P10 P12 p 13.5 P 15.S C2 C4 C6.5 C8 ClO Cl2 C14.5 c 16.5 
I. 0.79 0.92 0.88 0.96 1.00 1.38 1.17 1.38 1.65 0.79 1 0.79 0.83 0.88 0.88 0.88 1.00 1.13 
2 0.71 0.88 0.96 0.88 0.96 1.33 1.50 1' .42: 1.SS 0.79 0.79 0.71 0.75 0.96 0 .96 0.79 I .oo, 
3 0.58 0.71 0.7'9 0.916 0,88 1'.08 1.04 1.08 •• 38 0.58 0.67 0.6l 0.67 0.67 0 . 71 0.63 0.67 
4' 0.58 0.75 0.7' 0.71 1.04 1.00 1.25 1.2·9 1.42 0.63 0 .50 0.63 o.sa 0.63 0.79 0.79 0.83 
5 0.58 0.63 0 . 63 0.71 1.08 1.04 1.33 1.38 1.67 0.63 0 .63 0 .63 0.71 0.63 1.00 0.96 0.83 
6 0.63 0.58 0. 71 0.75 0.75 0.88 0.96 1.04 1.29 0.58 0 .67 0.58 0.67 0.71 0.79 0.75 0.83 
-
71 0.63 I 0.58 0 .67 0.63 0 .75 1. 1 7 1.46 1.46 1.54 0.54 0.63 0.63 0.54 0.75 0 .58 0.75 0.79 
9 0.63 0.63 0.67 0.63 0. 71 1.04 1.25 1.21 1.38 0.54 0.67 0.58 0.63 0.63 0.63 0.79 0.79 
9 0.67 0.75 0.79 0.92 1.00 1.1 3 1.29 1.46 1.54 0.67 0.71 0.79 0.75 0.88 0.92 0.96 1.00 
10 0.79 0.88 0.83 0.92 1.08 1.25 ' 1.38 1.54 1.63 1 0.71 0.75 0.79 0.96 1.00 1.00 1.04 1.17 
II 0.63 1 0.67 1.21 1.08 1.38 1.79 1 1.83 2.25 2.42 0.58 0.63 0.71 0.67 0.75 1.00 1.13 1.50 
12 0.63 0.67 0. 71 0.88 0.96 0.96 1.29 1.29 1.17 0.67 0.58 0.54 0. 71 0.83 0.83 0.79 1.00 
13 ! 0.58 0.75 0.96 0.88 1.25 1.46 1.63 1.63 1.96 0.71 0.58 0.67 0.88 0.75 1.25 1.13 1.17 
~~ 0.75 0.92 0.83 1.04 1.17 1.13 1.29 1.25 2.00 0.79 0.71 0.75 1.00 0.92 0.79 1.08 0.92 
15 0.88 1.08 1.08 1.63 1.58 1.96 1.79 1.79 2.00 0.79 0.71 0.88 1.04 1.04 1.21 1.21 I. 71 
r6 0.63 0. 71 o. 79 0.79 1.00 0.88 1.17 1.63 1.33 O.S:B I 0.54 0.63 0.67 0,83 0.75 0.75 1.09 
n 0.71 0.9·2 1' .08 •• 54 1.75 1.63 2.13 1.88 1.79 0.8l 0.67 0.75 0. '88 0.83 1.04 1.25 1.25 
10 0.88 1.00 , .ll 1.50 I ,92 1.75 2.04 1 2.08 1.83 1.U4 0.92 1' .00 1.25 I. 71 1.61 I. 7 I 1.79 
19 0.42 0.63 0.79 0.88 0.88 1.U8 1.00 1.50 1.21 0.54 '0 .• 54 0.58 0.71 0.63 0.71 0.79 0.83 
20 0.50 0.50 0.54 0.63 0.75 0.83 Loq LD4 1 1.17 0.46·f 0.46 0.50 0.54 0.63 0.63 o. 71 0.71 
21 0 . 92 0.88 0.96 1.00 1.13 1.00 1.29 1.58 1.58: 0.92 0.9ti 0.96 0 .'92 0.9·6 0 .92 •. 01 1.29 
22 0. 58 0.75 o. 71 0.88 1.25 1.5D J L67 1.46 1.50 0 .61 0.63 0 . 63 0.67 0.79 0 .. 89 0.92 1.13 
23 ' 0.58 o. 7'9 0.7'9 0.83 0.88 LOO l.. 7 1.54 1.3l 0.63 0 .67 0 .6·7 0 . 75 0.88 0..79 0.8'3 0.83 
2.4 0.63 0.63 0. 61 0 .. 75 0.81 1.00 I .21 1.63 1.46 0.63 0.67 0. 7'1 0.63 0,75 0. 79 1.,04 0.96 
25 0.63 0.67 0.75 0.88 0.88 0.96 LOS 1 .21 1.21 ] 0.61 0.75 0.67 0,7. 0.58 0.79 0.96 0.83 , 
26 0.83 0.88 1.00 1.29 1.25 1.' 7 1.42 1.92 1.88 0.88 O.BJ 0 .79 0.92 1.21 ,0.92 1.08 '.29 
I 27 ] 0.67 0.75> 0. 71 0.8:8 0.83 L13 1.17 1.33 IA2 0 .67 0.75 0.79 0 .• 71 01.7S 0.88 0.79 0. 79 
28 1 0.58 0,63 o. 75 0.75 0.88 0.88 0.96 1.42. L63 O.fil J 0.63 0.71 0.67 0.79 0. 71 0.92 0 . 92 
Page I 
M.A.R. Scores (EHCEL) 
29 0.50 0.67 0.83 1.04 1.08 1.21 1.33 2.08 1.83 0.63 0.67 0.75 0. 71 0. 71 0.96 0.96 1.25 
30 0.54 0.63 0.63 0.79 0.83 0.83 1.08 1.08 1.17 0.58 0.63 0.63 0.63 0.79 0 .83 0.83 0.88 
31 0.67 0.75 0.88 0.83 1.13 0.92 1.17 1.29 1.38 0.75 0.63 0.63 0.67 0.75 0 .96 0.88 0.96 
32 0.67 0. 71 0.75 0.79 0.96 0.83 1.00 1.21 1.17 0.71 0.67 0. 71 0.71 0.75 0.75 0.79 0.83 
33 0.71 1.08 0 .96 0.96 1.21 1.58 1.58 1.67 2.04 0.88 0.79 0.92 0.75 0.88 0.88 1.08 1.42 
34 0.63 0.71 0.79 0.92 0.88 1.04 1.33 1.71 1.46 0.63 0.67 0.58 0.71 0.79 0.79 0.92 1.25 
35 0.71 0.79 0.92 1.00 1.04 1.33 1.25 1.58 1. 71 0.79 0.79 0.79 1.00 0.92 0.88 1.08 1.00 
36 0.63 0.75 0.83 0.83 1.33 1.25 1.38 2.17 1.96 0.71 0.75 0 .75 0.83 1.04 1.08 1.08 1.29 
37 0.88 0.71 0.79 1.00 1.13 1.33 1.29 1.25 1.54 0.67 0.71 0.58 0.71 0 .75 0.92 1.04 0.96 
38 0.58 0.63 0 . 71 0.75 0.88 1.04 0.92 1.21 1.42 I 0,58 0.67 0.58 0.79 0.79 0.88 0.92 0.88 
39 0.54 0.54 0.58 0.63 0.79 0.88 0.75 1.04 1.13 0.54 1 0.50 0.54 0.54 0.58 0.50 0.67 0.67 
40 0.54 0.67 0.67 0.88 1.04 1.25 1.33 1.54 1.63 0.63 0.54 0.63 0.54 0.75 0. 71 1.04 1.29 
MEAN 0.66 0.74 0.81 0.92 1.05 1.17 1.31 1.49 1.56 1 0.68 0.68 0.70 0.75 0.82 0.87 0.95 1 1.04i 
S.D. 0.1 1 0.14 0.15 0.23 0.26 0.28 0.29 0.32 0.30 0 .12 0. I 1 0.12 0.15 0.20 0.20 0.20 0.27 
UNAIDED P2 P4 P6 P8 P10 P12 jP13.5 /P15.5 C2 I C4 C6.5 C8 C10 C12 c 14.5 C16.5 
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APPENDIX F 
Analysis of VarianQe Tables; Comparison of Mean Una ide~ MAR to M.~ _S.'s of All 
Polycarbonate "Treatments" 
22 
One Factor ANOVA-Repeated Measures for X1 .•. Xg 
Source· df· Sum of Squares: Mean Square: F-test: P value: 
Between subjects 39 13.682 .351 2.736 .0001 
Within subjects 320 41 .025 .128 
treatments 8 33.982 4.248 188.187 .0001 
residual 312 7.043 .023 
Total 359 54.707 
Reliability Estimates for- All treatments: .635 Single Treatment: .162 
One Factor ANOVA-Repeated Measures for X1 ... Xg 
Group: Count: Mean: Std. Dev .: Std. Error: 
Unaided 40 .655 . 11 4 .018 
P2 40 . 744 .138 .022 
P4 40 . 811 .152 .024 
P6 40 .915 .23 .036 
P8 40 1.053 .265 .042 
2 
7 
One Factor ANOVA-Repeated Measures for X1 ... Xg 
Group_: Count: Mean: Std . Dev.: Std. Error: 
P10 40 1 .173 .282 .045 
P12 40 1.306 .294 .046 
P14 40 1.488 .315 .05 
P16 40 1.56 .297 .047 
3 
7 
One Factor ANOVA-Repeated Measures for X1 .•. X9 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F -test: Dunnett t: 
Unaided vs. P2 -.089 . o 55· .877 2.649 
Unaided vs. P4 -.1 55 . os s· 2.678* 4.629 
Unaided vs. P6 - .26 . 0 55* 7 .458* 7.724 
Unaided vs. P8 -.398 . 0 55* 1 7 . 5. 11 .832 
Unaided vs. P1 0 -.51 7 . 0 55. 29.604* 15.389 
4 
* Significant at 90% 7 
One Factor ANOVA-Repeated Measures for X1 ... Xg 
c ompanson: Mean I .. F' h PLSD 1s er S h ff F c e e -test: D unnett t: 
Unaided vs. P12 -. 65 . 0 55* 46 .794* 19.348 
Unaided vs. P14 -.832 . 0 55. 76.76* 24.781 
Unaided vs. P16 -.905 . 0 55* 90.661 * 26 .931 
P2 vs. P4 -.067 . 0 55* .49 1. 979 
P2 vs. P6 - . 1 71 . 055. 3.22* 5.075 
5 
• Significant at 90% 
One Factor A NOVA-Repeated Measures for X1 ... Xg 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
P2 vs. P8 - .309 . 0 55. 10.541* 9.183 
P2 vs. P10 -.428 . 0 55. 20.289* 12 .74 
P2 vs. P12 - . 5 61 . 0 55. 34.857* 16.699 
P2 vs. P14 - . 7 44 . 0 55. 61.225* 22.131 
P2 vs. P16 - .81 6 . 0 55. 73.702. 24.282 
6 
. Significant at 90% [7 
One Factor ANOVA-Repeated Measures for X1 ..• Xg 
c om_f>anson: M ean I .. F' h PLSD 1s er S h ff F t t D c e e - es : unne It t 
P4 vs. P6 - . 1 04 . 0 55* 1.1 98 3.096 
P4 vs. P8 -.242 . 055* 6.486* 7 .203 
P4 vs . P10 -.362 . 0 55* 14.474* 10.761 
P4 vs. P12 -.495 . 0 55* 27 . 083. 14.72 
P4 vs. P14 -. 677 . o 5 s· 50. 762* 20.1 52 
7 
* Significant at 90% 
One Factor ANOVA-Repeated Measures for X1 ... Xg 
Comparison: [v1ean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
P4 vs. P1 6 -. 749 . 0 55* 62.175* 22.303 
P6 vs. P8 -.1 38 . 0 55* 2.1 09* 4.108 
P6 VS. P10 - .258 . 0 55. 7.344* 7.665 
P6 vs. P12 -.391 . 0 55* 16 .889* 11.624 
P6 vs. P14 -.573 . 05 5. 36.364 * 17.056 
8 
* Significant at 90% 7 
One Factor A NOVA-Repeated Measures for X1 ••• Xg 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F -test : Dunnett t: 
P6vs.P16 - .645 . 0 55* 46.113* 19.207 
P8vs.P10 -. 1 2 . 0 55. 1.582 3.557 
P8 vs. P12 -.253 . 0 55. 7.061* 7 .516 
P8 vs. P14 -.435 . 0 55. 20.958* 12.948 
P8 vs. P16 -. 507 . 05 5* 28 .498* 15.099 
9 
• Significant at 90% [7 
One Factor ANOVA-Repeated Measures for X1 .•. Xg 
c ompanson: M ean O'ff I .. F' h PLSD 1s er S h ff F c e e -tes : 0 unne tt t 
P10 vs. P12 -.1 33 . 0 55* 1.959* 3.959 
P1 0 vs. P14 -.31 5 . 0 55* 11 .025 * 9.391 
P1 0 vs. P16 -.388 . 055* 16.652* 11 .542 
P12 vs. P14 -. 1 8 2 .055* 3.689* 5.432 
P12 vs. P16 -.255 . 0 55* 7.188* 7.583 
10 
* Significant at 90% 
One Factor ANOVA-Repeated Measures for X1 ••• Xg 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F -test: Dunnett t: 
IP14vs.P16 1-.072 ,. 0 55* 1.578 
* Significant at 90% 
1 1 
7 
APPENDIXG 
Analysis of Variance Tables: Comparison of Mean Unaided M.A.R. to M.A.R.'s of All CR39 
"Treatments" 
23 
One Factor ANOVA-Repeated Measures for X1 ... Xg 
Source: d f: Sum of Squares: Mean Square: F-test: P value : 
Between subjects 39 6.923 .178 6.057 .0001 
Within subjects 320 9.378 .029 
treatments 8 5.992 .749 69 .03 .0001 
residual 312 3 .385 . 011 
Total 359 16.301 
Reliability Estimates for- All treatments: .835 Single Treatment: .36 1 
7 
One Factor ANOVA-Repeated Measures for X1 Xg 
G roup: c oun : M ean: Std D ev.: Std E rror: 
Unaided 40 .655 . 11 4 .018 
C2 40 .68 .121 .019 
C4 40 .676 . 1 06 .017 
C6 40 .696 . 11 7 .018 
C8 40 . 751 . 154 .024 
2 
One Factor ANOVA-Repeated Measures for X1 ... Xg 
G roup_: c aunt : M ean: S d D t . ev.: S d E t . rror: 
C10 40 .822 .1 99 .031 
C12 40 .873 .197 .031 
C14 40 1 .947 .196 .031 
C16 40 1.043 .267 .042 
3 
One Factor ANOVA-Repeated Measures for X1 .•. Xg 
c ompanson: M ean I .. F' h PLSD IS er Shff Ft t D c e e - es : unne tt t 
Unaided vs. C2 -.025 .038 .141 1.063 
Unaided vs. C4 -. 0 21 .038 . 1 02 .902 
Unaided vs. C6 -. 04 . 038* .373 1. 728 
Unaided vs. C8 -. 096 . 0 38 * 2.123* 4.121 
Unaided vs. C1 0 -.1 66 .038* 6.368* 7.137 
4 
* Significant at 90% 
One Factor ANOVA-Repeated Measures tor X1 ••. Xg 
c ompanson: M ean I .. F h PLSD IS er S h ff F c e e -test: D unnett t: 
Unaided vs. C12 -.21 7 .038. 1 0 .899* 9.338 
Unaided vs. C14 -.292 . 03 8 * 19.577* 12 .515 
Unaided vs. C16 -.388 . 0 38 * 34.595* 16.636 
C2 vs. C4 .004 .038 .003 . 161 
C2 vs. C6 -. 0, 6 .038 .055 .665 
5 
* Significant at 90% 
One Factor ANOVA-Repeated Measures tor X1 ..• Xg 
c ompanson: M ean I .. F" h PLSD IS er S h ff F c e e -test: D unnett t: 
C2 vs. C8 -. 0 71 . 0 3 8. 1., 7 3.059 
C2 vs. C10 -., 42 . 038* 4.613* 6.075 
C2 vs. C12 - . 1 9 3 . 0 38 * 8. 56* 8.275 
C2 vs. C14 -.267 . 0 38 * 16.394* 11 .452 
C2 vs. C16 -.363 . 038* 30.317* 15.574 
6 
* Significant at 90% 
One Factor ANOVA-Repeated Measures for X1 ••. Xg 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
C4 vs. C6 -. 01 9 .038 .085 .826 
C4 vs. C8 -.075 . 038* 1.296 3.22 
C4 vs. C10 -.1 45 . 038* 4.861* 6.236 
C4 vs. C12 -. 1 9 6 . 038* 8.896* 8.436 
C4 vs. C14 - .271 . 038. 16.858* 11.613 
7 
* Significant at 90% 7 
One Factor ANOVA-Repeated Measures for X1 ••• Xg 
c ompanson: M ean I .. F h PLSD IS er S If F che e -test: D unnett t: 
C4vs.C16 -.367 . 038* 30 . 947* 15.735 
C6 vs. C8 -.056 . 038* . 716 2.393 
C6 vs. C1 0 -.1 26 . 038. 3.658* 5.409 
C6 VS. C12 - . 1 77 .038* 7.238* 7.61 
C6 vs. C14 -.251 . 038. 14 .544* 10.787 
8 
* Significant at 90% 
One Factor ANOVA-Repeated Measures for x, ••• Xg 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F -test: Dunnett t: 
C6vs.C16 - .34 7 .038* 27. 782* 14.908 
C8 vs. C10 -.0 7 .038* 1.137 3.016 
C8 vs. C12 - .1 21 .038* 3.40 1* 5.216 
C8 vs. C14 - . 1 96 . 038* 8 . 806* 8.393 
C8vs.C16 - .292 . 038* 19 .577* 12.515 
9 
* Significant at 90% 7 
One Factor ANOVA-Repeated Measures for x1 .. ·. Xg 
Com_garison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
C10vs.C12 -.051 .038* .605 2.2 
C10vs.C14 -.1 25 . 038* 3 . 614* 5.377 
C10 vs. C16 -.221 .038* 11.278* 9 .4 99 
C12 vs. C14 -.07 4 .038* 1.262 3.177 
C12vs. C16 -.1 7 . 038 * 6.658* 7.298 
1 0 
• Significant at 90% 7 
One Factor ANOVA-Repeated Measures for X1 •.• Xg 
Comparison : Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
I C14 vs. C16 1-.096 1- 038* 12.123* 
* Significant at 90% 
1 1 [7 
APPENDIX H 
Ana!YsJs of' Varjance Jables: CompatiiQO of Q1fferenonBetween All CR39 and 
Polycarbonate "Treatments" 
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One Factor ANOVA-Repeated Measures for X1 ... Xa 
Source· d f . Sum of Squares· Mean Square: F-test: P value: 
Between subjects 39 4.308 . 1 1 1.977 .0009 
Within subjects 280 15 .648 .056 
treatments 7 8.466 1 .209 45.98 .0001 
residual 273 7 . 181 .026 
Total 319 19.956 
Reliability Estimates for- All treatments: .494 Single Treatment: .1 09 
One Factor ANOVA-Repeated Measures tor X1 ... Xa 
G roup: c ount: M ean: S d D t ev.: S d E . t rror: I 
P2-C2 40 .064 .07 . 011 
P4-C4 40 .134 .128 .02 
P6-C6 40 .219 . 1 79 .028 
P8-C8 40 .302 .192 .03 
P10-C10 40 .351 .253 .04 
2 
One Factor ANOVA-Repeated Measures tor X1 ... Xs 
Group: Count: Mean: Std. Dev.: Std. Error: 
P12-C12 40 .433 .207 .033 
P14-C14 40 .541 .232 . 037 
P16-C16 40 .517 .21 .033 
3 [7 
One Factor ANOVA-Repeated Measures for X1 ••• Xa 
c ompanson: M ean I .. F h PLSD 1s er S h ff F c e e -tes : D unne tt t 
P2-C2 vs. P4-C4 -.07 . 0 6 * .536 1.937 
P2-C2 vs. P6-C6 -.1 55 . 0 6 * 2. 61'* 4.274 
P2-C2 vs. P8-C8 -.237 . 0 6 .. 6.114* 6.542 
P2-C2 vs. P1 O-C1 0 - .287 . 0 6 .. 8.916* 7.9 
P2-C2 vs. P12-C12 -.368 . 0 6 * 14.729* 1 0.154 
4 
• Significant at 90% 
One Factor ANOVA-Repeated Measures for X1 •.. Xa 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
P2-C2 vs. P14-C14 -.477 . 0 6. 24.688* 13.146 
P2-C2 vs. P16-C16 -.453 . 0 6. 22.28 9* 12.491 
P4-C4 vs. P6-C6 -.085 . 0 6 * .78 2.337 
P4-C4 vs. P8-C8 -. 1 6 7 . 0 6. 3.029* 4.605 
P4-C4 vs. P10-C10 -.21 6 . 0 6. 5.079* 5.963 
5 
* Significant at 90% 
One Factor ANOVA-Repeated Measures tor X1 ... Xa 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
P4-C4 vs. P12-C12 -.298 . 0 6. 9.646* 8.217 
P4-C4 vs. P14-C14 -.407 . 0 6 * 17.948* 11 .209 
P4-C4 vs. P16-C16 -.383 . 0 6 * 15.912* 10.554 
P6-C6 vs. P8-C8 -.082 . 0 6 * .735 2.268 
P6-C6 vs. P1 O-C1 0 -.1 32 . 0 6. 1.878* 3.626 
6 
* Significant at 90% 7 
One Factor ANOVA-Repeated Measures for x1 .•. Xa 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F-test: Dunnett t: 
P6-C6 vs. P12-C12 -.21 3 . 0 6. 4.939* 5.88 
P6-C6 vs. P14-C14 -.322 . 0 6. 11.244* 8.872 
P6-C6 vs. P16-C16 - .298 . 0 6. 9.646* 8.217 
P8-C8 vs. P1 O-C1 0 -.049 .06 .263 1.358 
P8-C8 vs. P12-C12 -. 1 31 . 0 6. 1.864* 3 .612 
* Significant at 90% 
One Factor A NOVA-Repeated Measures for X1 ... Xs 
Comparison: Mean Diff.: Fisher PLSD: Scheffe F -test: Dunnett t: 
P8-C8 vs. P14-C14 -.239 . 0 6. 6.23* 6.604 
P8-C8 vs. P16-C16 -.21 6 . 0 6. 5.056* 5.949 
P10-C10 vs . P12-C12 - .082 . 0 6. .726 2.254 
P1 O-C1 0 vs. P14-C14 - . 1 9 . 0 6. 3.931* 5.246 
P1 O-C1 0 vs . P16-C16 - .1 66 . 0 6 * 3.011* 4.591 
8 
. Significant at 90% [7 
One Factor ANOVA-Repeated Measures for X1 ... Xs 
c ompanson: M ean I .. F' h PLSD 1s er S h ff F c e e -tes : D t t unne t 
P12-C12 vs. P14-C14 -.1 08 . 0 6 * 1.279 2.992 
P12-C12 vs . P16-C16 - .085 . 0 6. .78 2.337 
P14-C14 vs. P16-C16 .024 .06 .061 .655 
• Significant at 90% 
9 
APPENDIX I 
Statement of Informed Consent 
A statement of informed consent was completed by each subject in this study. The 
statements are on file with the Assistant Dean, College of Optometry, Pacific University. 
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Statement of Informed Consent 
1. Title of Project: Image Quality as a Function of Induced 
Dispersion With Polycarbonate and CR39 Lenses. 
2. Principal Investigator: Lawrence D. Hampton, O.D., 
357-3199. 
3. Faculty Advisor: Niles Roth, M.Opt., Ph.D., 357-7598 
4. Location: Pacific University College of Optometry, Forest 
Grove, OR 
5. Date: Summer, 1989 
6. Description of Project. You have been asked to participate 
in a study which will assess the clarity of vision through certain 
types of spectacle lens materials. I will be measuring your distance 
visual acuity unaided and through each of sixteen lenses. The 
lenses, in the form of prisms, will be placed in a trial frame which 
you will wear during the testing. 
The measurement of visual acuity will consist of this: You will 
sit in a chair and view a video monitor placed several feet away. On 
the screen you will see standard acuity chart letters which you will 
be asked to read. Letters of varying sizes will be shown to you to 
determine your visual acuity. 
The testing will be performed one eye at a time. For each eye, 
then, testing will include seventeen measurements of visual acuity. 
If both your eyes have 20/20 or better unaided distance visual 
acuity, both eyes will be tested. If not, only the 20/20 eye will be 
tested. 
It is estimated that the entire sequence will require thirty 
minutes per eye. Each participant will be involved in one session 
only. 
This study is part of a master's thesis project which will also be 
submitted for publication in an optometric journal. The findings will 
be used to predict the clarity of vision which can be achieved with 
the different lens materials, information which will be of use to 
practicing optometrists. 
7. Description of Risks. There are no foreseeable risks to 
subjects. Customary care will be observed with the trial frame and 
lenses so that you are not exposed to sharp corners or rough 
handling near the face. 
The laboratory will be kept orderly and the room lights will on 
at all times. 
It is expected that your vision will be blurred or distorted by 
some of the lenses. In the extreme case this may cause you to 
become uneasy or uncomfortable during testing. If this occurs, I 
encourage you to let me know so that we can interrupt the testing 
for your comfort. Interrupting will not invalidate the findings. If 
necessary testing can be rescheduled or discontinued entirely. 
Even in the absence of discomfort, the testing sequence may be 
fatiguing due to its length. 
It is not expected that you will incur any costs as result of your 
participation in this study, except for transportation to and from the 
College of Optometry. 
8. Benefits to Subjects. Though you will not be paid for your 
participation in this study, I do offer my sincere personal thanks for 
your help. The information gained will provide eye care 
practitioners with the knowledge necessary to advise their patients 
in the selection of the best lens material for their needs. 
9. Withdrawal. Your participation in this study is wholly 
voluntary. If you decline to participate or ask to withdraw, it will 
involve no penalty to you or loss of any benefits to which you are 
otherwise entitled. You may withdraw at any time merely by 
notifying me of your wishes. Similarly, I reserve the privelege of 
cancelling your participation if I decide it is necessary, and in such 
case there is no penalty to you whatever. 
10. Number of Subjects. Twenty or more subjects have been 
recruited for this study, for a total of forty eyes with 20/20 or better 
visual acuity. 
11. Confidentiality. Your visual acuity findings will be filed 
under your name until all data have been gathered. During and after 
the analysis of data only your initials will be used. At no time will 
your results be discussed or released under your name without your 
personal consent. 
12. Compensation and Medical Care. If you are injured in this 
experiment it is possible that you will not receive compensation or 
medical care from Pacific University, myself, or any organization 
associated with the experiment. All responsible care, however, will 
be used to prevent injury . 
13. Offer to Answer Inquiries. If at any time you have 
questions of any sort about the study or your participation in it, 
please ask me. If you are not satisfied with the answers you receive, 
please call Dr. Roth or Dr. James Peterson at 357-0442. Participation 
in this study does not make you a patient of the Pacific University 
College of Optometry Clinic, and all inquiries should be directed to me 
or to my faculty advisor, Dr. Roth. 
I have read and understand the above. I am 18 years of age or over 
(or this form is signed for me by my parent or guardian). 
Printed name 
Signature ______________________________________ D ate _________ _ 
Address ___________________________ Phone _________________ _ 
City State /Zip ______ _ 
Name and address of a person not living with you who will always 
know your address: 
APPENDIX J 
IRB Submission 
Prior to initiating the study it was necessary to submit this paper to the local area 
Institutional Review Board. Their review and approval of the protocol is a requirement 
of all studies which make use of human subjects. 
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I. Project title. 
IRB Submission 
Lawrence D. Hampton, O.D. 
Image Quality as a Function of Induced Dispersion with Polycarbonate and CR39 
Lenses. 
II. Abstract. 
Polycarbonate is an extremely strong plastic which is commonly used for face 
shields and helmets. It is increasingly recommended as the material of choice in 
prescription and nonprescription safety glasses, and it is being used in street-wear 
spectacles as well. A drawback of the material, however, is its high dispersion. This is 
the characteristic which causes prisms to separate light into its component colors. It 
causes color fringes and blur in the periphery of prescription lenses, in increasing 
degree with stronger lens powers due to their greater prismatic effect. The dispersion 
characteristics of polycarbonate are twice that of glass and of the most commonly used 
spectacle lens material, CR39 plastic. 
Although this trait of polycarbonate is widely known, the blur that it causes has 
not been adequately measured. In this study I will measure the loss of optical clarity 
caused by prisms of polycarbonate and of CR39. It will then be possible to predict the 
blur which will result when given lens powers in those materials are prescribed. 
Ill. Location of project. 
The study will be conducted in laboratory facilities in the Pacific University 
College of Optometry. 
IV. Project Overview, 
The study consists of measuring subjects' visual acuity through polycarbonate 
and CR39 prisms. 
Twenty or more subjects will be selected from Pacific University faculty, staff, 
students, and family members. The subjects will be selected based on their having 
20/20 or better uncorrected distance visual acuity. (The total number of eyes to be 
tested is 40; if some subjects have the required unaided visual acuity in one eye only, 
additional subjects will be recruited in order to achieve that total.) 
Eight prisms each of polycarbonate and of CR39 are being fabricated. Each group 
of eight prisms comprises a series of increasing powers, from 2 prism diopters 
through 16 prism diopters. The prisms are being cut and edged in the same way as 
spectacle lenses and are being mounted in metal trial lens rings. 
Subjects will be seated wearing a trial spectacle frame. The unaided visual 
acuity of each eye will be measured using the Baylor Visual Acuity Tester (BVAT), a 
video display terminal controlled by a microprocessor. A "staircase" (bracketing) 
technique will be used for measuring the visual acuity. Each of the sixteen prisms will 
then be placed in the trial frame before the tested eye and the visual acuity through each 
will be measured in the same manner. · 
V. Risks . 
There are no expected risks to the subjects. No procedures which can be 
considered invasive are to be performed, and the subjects' eyes are not to be touched. 
Trial spectacle frames will be placed before the subjects' eyes, and the tested 
prisms will be inserted and removed while the frame is in place. During that sequence, 
untoward events such as bumping the nose or the eye are conceivable but are not 
1 
expected. The frame and the prisms will be carefully handled, and those precautions 
should prevent such accidents. 
Since the vision through many of the prisms is expected to be distorted to some 
degree, there is the possibility that subjects will become uneasy and, in the extreme 
case, nauseated. Breaks from testing, cool compresses, rescheduling, and 
discontinuation of testing if necessary will be provided for the subjects' comfort. 
The testing sequence may become protracted and taxing, resulting in fatigue. 
There will be the normal concerns for safety in traveling to the building, 
walking through the halls, and passing in and out of the laboratory. The laboratory will 
be kept orderly to minimize that risk, and the room light will be turned up while 
subjects are passing in and out. 
VI. Monitoring procedures. 
Clear instructions will be provided to the subjects prior to testing. Particular 
emphasis will be placed on discomfort and fatigue, and subjects will be encouraged to 
interrupt testing if they become uncomfortable. 
An informed consent form will be read and signed by each subject prior to 
testing, and opportunity for questions will be provided. 
1 will be performing all testing, and during testing I will be continually 
monitoring the subjects for any evidence of discomfort. 
Any subject who complains of dizziness or nausea will be encouraged not to drive 
until feeling normal. The day after testing I will telephone any subjects who have any 
adverse responses, in order to confirm that they have returned to normal and have had 
no recurrences of discomfort. 
VII. Sample of Informed Consent Form. 
1. Title of Project: Image Quality as a Function of Induced Dispersion With 
Polycarbonate and CR39 Lenses. 
2. Principle lnvestioator: Lawrence D. Hampton, O.D., 357-3199 
3. Faculty Advisor: Niles Roth, M.Opt., Ph.D., 357-7598 
4. Location: Pacific University College of Optometry, Forest Frove, OR 
5. ~ Summer, 1989 
6. Description of Project. You have been asked to participate in a study which 
will assess the clarity of vision through certain types of spectacle lens materials. I 
will be measuring your distance visual acuity unaided and through each of sixteen 
lenses. The lenses, in the form of prisms, will be placed in a trial frame which you 
will wear during the testing. 
The measurement of visual acuity will consist of this: You will sit in a chair and 
view a video display terminal placed several feet away. On the screen you will see an 
upper case letter E, but it will not necessarily be upright. I will ask you to tell me if 
the limbs of the letter point toward the right, the left, up, or down. Letters of varying 
sizes will be shown to you to determine your visual acuity. 
The testing will be performed one eye at a time. For each eye, then, testing will 
include seventeen measurements of visual acuity. If both your eyes have 20\20 or 
better unaided distance visual acuity, both eyes will be tested. If not, only the 20/20 
eye will be tested. 
It is estimated that the entire sequence will require thirty minutes per eye. 
Each participant will be involved in one session only. 
This study is part of a master's thesis project which will also be submitted for 
publication in an optometric journal. The findings will be used to predict the clarity of 
vision which can be achieved with the different lens materials, information which will 
be of use to practicing optometrists. 
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7. Description of Risks. There are no foreseeable risks to subjects. Customary 
care will be observed with the trial frame and lenses so that you are not exposed to 
sharp corners or rough handling near the face. 
The laboratory will be kept orderly and the room lights will be turned up at all 
times. 
It is expected that your vision will be blurred or distorted by some of the lenses. 
In the extreme case this may cause you to become uneasy or uncomfortable during 
testing. If this occurs, l encourage you to let me know so that we can interrupt the 
testing for your comfort. Interrupting will not invalidate the findings. If necessary 
testing can be rescheduled or discontinued entirely. 
Even in the absence of discomfort, the testing sequence may be fatiguing due to 
its length. 
It is not expected that you will incur any costs as result of your participation in 
this study, except for transportation to and from the College of Optometry. 
8. Benefits to Subjects. Though you will not be paid for your participation in 
this study, I do offer my sincere personal thanks for your help. The information gained 
will provide eye care practitioners with tne knowledge necessary to advise their 
patients in the selection of the best lens material for their needs. 
9. Withdrawal. Your participation in this study is wholly voluntary. If you 
decline to participate or ask to withdraw, it will involve no penalty to you or loss of any 
benefits to which you are otherwise entitled. You may withdraw at any time merely by 
notifying me of your wishes. Similarly, I reserve the privelugo of cancelling your 
participation if I decide it is necessary, and in such case there is no penalty to you 
whatever. 
10. Number of Subjects. Twenty or more subjects have been recruited for this 
study, for a total of forty eyes with 20/20 or better visual acuity. 
11. Confidentiality. Your visual acuity findings will be filed under your name 
until all data have been gathered. During and after the analysis of data only your 
initials will be used. At no time will your results be discussed or released under your 
name without your personal consent. 
12. Compeosatfan and M~dica! Car~. If you are injured in this experiment it is 
possible that you will not rece ive compensation or medical care from Pacific 
University, myself, or any organization associated with the experiment. All 
responsible care, however, will be used to prevent injury. 
13. Offer to Answer Inquiries. If at any time you have questions of any sort 
about the study or your participation in it, please ask me. If you are not satisfied with 
the answers you receive, please call Dr. Roth or Dr. James Peterson at 357-0442. 
Participation in this study does not make you a patient of the Pacific University College 
of Optometry Clinic, and all inquiries should be directed to me or to my faculty advisor, 
Dr. Roth. 
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I have read and understand the above. I am 18 years of age or over (or this form is 
signed for me by my parent or guardian). 
Printed name _________________________ _ 
Signature---------------------------
Date ________________ _ 
Address~----------------Phone ____________ __ 
City ------------------State /Zip ____________ __ 
Name and address of a person not living with you who will always know your 
address ___________________________________ ___ 
VIII. Pates of Project . All data collection requiring participation of subjects will be 
conducted between 1 June 1989 and 1 September 1989. 
IX. Principal Investigator: Lawrence D. Hampton, O.D. 
Faculty Advisor: Niles Roth M.Opt., Ph.D. 
4 
APPENDIX K 
Instructions to Subject 
These instructions were read to each subject prior to testing, in order to standardize the 
information provided to each. 
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Instructions to Subject 
I will show you a row of five letters. They may be clear or blurry, large or 
small. Your task is to read them as best you can. You will have eight 
seconds; after that the screen wi 11 go blank. 
Here is an example. Take note of how long eight seconds lasts. (Show 
20/40 example.) Here's another. (Show 20/25 example.) Note that the 
eight seconds is plenty of time if the letters are easy to read, but that it 
may press you a ·little if they are small or blurry. (Show 20/15 example.) 
Please try your best, and it's all right to guess. If you can't read the 
letters, I'll increase their size until you can. If you can read them, I'll 
reduce their size unt i 1 you can't. 
It's perfectly all right to correct yourself or change your mind within the 
eight seconds. 
Please don' t squint, and be sure to hold your head straight; don't t i 1 t or 
turn your r,ead to act"'lieve better vision. 
We will do this several times with the naked eye and through eacr1 of the 
prisms 
Do you have any questions? Be sure to interrupt any time if you do, or if 
you want to take a break or adjust your position or the trial frame. 
Then let's begin. 
APPENDIX L 
Data Collection Protocol 
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Data Collection Protocol 
1. Subject (S) is asked to arrive fifteen minutes before the scheduled 
time of testing. s sits at a desk in the hallway and reviews and signs ttie 
Informed Consent Form. When that is completed, Experimeter (E) 
retneves the signed consent form and offers the opportunity to ask 
ouest1ons. E exola1ns that the 1nstruct1ons w111 be repeated at tne 
beginning of the testing sequence, and at that time another opportunity to 
ask Questions will be presented. 
2. s is seated in the ex ami ni ng chair. Trre tria 1 frame is placed on the 
subject and adjusted for comfort and proper alignment, to include 
approximately ten degrees of pantoscopic tilt. E places an occluder in the 
trial frame before the non-tested eye. If t1oth of S's eyes are to be tested, 
the right eye is tested flrst (the left eye is covered first.) The room 
lights overs and E are left on during testing. 
3. E reads the instructions to sand demonstrates the testing method. 
Final Questions are answered. 
4. E measures S's unaided monocular visual acuity (see Test1ng Method). 
Using the preprinted data sheets, E enters the Snellen denominator for 
each end point. 
5. The prisms are then placed one at a time in the trial frame, in no 
part 1 cul ar sequence, and the procedure desert bed in paraqraph 4 is 
followed for each. The prisms are oriented obliQuely (base apex line@ 45 
OD,@ 135 OS) so that the prisms are not aligned w1th the predominant 
horizontal and vertical elements of the stimulus optotypes. 
6. If the other eye is to be tested, the occluder is reversed and paragraphs 
4 and 5 are repeated. 
7. sis reminded during testing that he/she should request a break if 
desired for fatigue or di scornf ort. 
8. At the conclusion of testing. E thanl<s Sand escorts S to the door. E 
reminds S that there may be some eye fatigue but that it should go away 
within a few hours. S is asked to notl fy E if it does not. 
APPENDIX M 
Testing Procedure 
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Testing Procedure 
1. Definlt ions and Parameters 
1. Subject (5) is shown a row of five letters per- trial. Four or five 
correct (at least 80% correct) is a correct response. Less than four is an 
if7COIT&ct response. 
2. When the optotype size exceeds 20/42.5) the BVAT automatically 
reduces the number of letters per row to three. In this case) two or three 
of the three letters must be read for a correct response (at least 66.6% 
correct). 
3. Sis given eight seconds per trial, and may make changes as desired 
within that period. 
4. A run is a series of trials which concludes in an end point. The number 
of trials in a run is not fixed; at the minimum it consists of one correct 
response paired with one incorrect response one step smaller. 
5. The end point of a run occurs when S gives an incorrect response which 
fo 1 lows one or more correct responses) or gives a correct response 
following one or more i!lcorrect responses. 
6. The visual acuity indicated by a run is the smallest letter size for 
which a correct response is given. The Snellen denominator for this 
acuity Jeve l is recorded. 
5. There are three runs per testing condition. Testing includes seventeen 
conditions per eye (sixteen prisms plus the naked eye). 
6. Each time the letter size is changed, the letters are changed. 
7. S is asked to close the eyes when prisms are being changed. 
I L Psychophysical T echnique 
1. Start each set of three runs with a letter size expected to be above 
thresl1o 1 d. 
2. If the response to the first trial Cor any subsequent trial) is correct, 
reduce the stimulus size one step and change the letters. Repeat until an 
;i;correct response results. This ends the run. 
3. If tr',e response to the first trial (or any subsequent trial) is incorrect, 
change the lett~rs and present the next larger size. Repeat until a correct 
response resu 1 ts. This ends the run. 
4. This is an adaptation of the method of limits. The stopping point 
(optotype size) of the first run becomes the starting point of the second 
run. The stopping point of the second run becomes the starting point of 
tt1e tt1ird run. This means the first run starts above thresho 1d, the second 
run begins below the threshold determined by the first run, and the third 
run starts at or above the threshold indicated by the second run. (If the 
results of the three runs are not the same, which is common, then the 
averaged threshold may not be bracketed in exactly that manner. The 
procedure, however, is standardized as described.) 
APPENDIX N 
Sample Data Form 
This form was utilized in recording the raw data. The Snellen visual acuity denominator 
at the end point of each run was recorded by the experimenter. Those data points were 
then entered onto the same form in a spreadsheet program which calculated the M.A.R. 
equivalent for each entry. The program also calculated the mean M.A.R. for each subject 
for each testing condition, or "treatment". That number was transferred onto the 
spreadsheet in APPENDIX E, which calculated mean M.A.R.'s for the entire population of 
40 eyes. 
30 
Data Form (BUAT) 
Subject: ~Age:1 l 00 /OS l F I M 1 l l i 1 ! ! 1 ! 
:= : : i 1: I I :: I 1 I I 1 :1 : I : I :I: I I : I I : 
! POL YCRRBONATE j 1 1 1 ! ! 
.............. 01 a !P2 ! a ! P4! a iP6! a iPS) a 1P10 a i P12! a !P13.5! a !P15.5 i a 
1 · · ····· ···· ··· ···············~-=--+--=----+-...::.....:=----t---=;___;~-=--+--=-......;-..:....:-+~-+--+---+---+----r----t_,;,--i~~~--=---t-.:._:_..=...:..:::..t--=-....., 
Trial no.l 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
,.............................. .............................................. ................ ............... ................ .. .... ...... ... ............. .. ................. . .. ................ +--__ 
2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
, ......... ....................................................................................... ........... .. .............. ............... ................................. .................. ~~
3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
--~........................... "'"'*' 0 00 **'*' iO OOi **"' ! 0 oo: ***' ~ 0 001 **'* l 0 oo: *'*"' ! 0 001 *** i 0 OO! **'*' ! 0 OOi *** .0 ...... 0 .... 0 ... BLtg .. a . • · ; : • ~ : · : : .. : : " : : . : : " ' . 
i i C2! a! C4! a !C6.5l a i C8! a !ClO! a !C12! a !C14.5! a [C16.5j a 
.............................. ~ ................ : ............... ~~+--=-+--=-=-t---=:.__;...:.....:~.j----+---+----+-..::;....:.~,__-~__.:.;.-i-..;:;;_-t-=-=-~t--~+-=-..:....::..~---=~ 
Trial no.ll *** i *'** 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
..... ........................................... : .............................................................. .... ........................... .................................................... ~~
21 *** i *** 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
................................ ... ............. : .......................................................................................... , .................................................... ~~
3! "'** l *** 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
.............................. ~ ................ :............... . . 
1
" 1 *** j *** *** iO OOi *"* !Q OOi *'**' lQ OOi >f<>f:>f-: 10 00! *** lO OO! *** !O OO! ***' iO OOi **'* 0 00 auH. a ~ : : I : : I : : I = : • ~ = • = : • : : • = .. 
APPENDIXO 
.Qa1a 
The raw data is filed with the Assistant Dean, College of Optometry, Pacific University. 
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